Avidity Biosciences, Inc. (RNAM)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch RNAM
See up to 3 months of RNAM. The 7-day demo opens the 1M and 3M ranges and puts RNAM on your watchlist.
Start 7-day demoLatest RNAM insider trades
About Avidity Biosciences, Inc. (RNAM)
The SEC lists Avidity Biosciences, Inc. under CIK 0001599901, in pharmaceutical preparations. It is grouped with Health Care companies on this site.
RNAM Form 4 activity by transaction type, last 90 days
No Form 4 activity for RNAM in the last 90 days.
RNAM insider transactions (Form 4)
13559 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Teresa McCarthy - Officer | Derivative | Common Stock | 165,296 footnote F1 | - footnote F1 | - | |
| Teresa McCarthy - Officer | Derivative | Stock Option (Right to Buy) | 106,000 | - footnote F2 | - | |
| Teresa McCarthy - Officer | Derivative | Stock Option (Right to Buy) | 65,000 | - footnote F2 | - | |
| Teresa McCarthy - Officer | Derivative | Stock Option (Right to Buy) | 57,500 | - footnote F2 | - | |
| Teresa McCarthy - Officer | Derivative | Stock Option (Right to Buy) | 108,000 | - footnote F2 | - | |
| Teresa McCarthy - Officer | Derivative | Stock Option (Right to Buy) | 54,000 | - footnote F2 | - | |
| Teresa McCarthy - Officer | Derivative | Stock Option (Right to Buy) | 78,000 | - footnote F2 | - | |
| Teresa McCarthy - Officer | Derivative | Stock Option (Right to Buy) | 50,000 | - footnote F2 | - | |
| ||||||
| Tamar Thompson | Derivative | Common Stock | 6,692 footnote F1 | - footnote F1 | - | |
| Tamar Thompson | Derivative | Stock Option (Right to Buy) | 10,034 | - footnote F2 | - | |
| Tamar Thompson | Derivative | Stock Option (Right to Buy) | 13,489 | - footnote F2 | - | |
| Tamar Thompson | Derivative | Stock Option (Right to Buy) | 22,000 | - footnote F2 | - | |
| Tamar Thompson | Derivative | Stock Option (Right to Buy) | 22,000 | - footnote F2 | - | |
| ||||||
 Michael F. Maclean - Officer | Derivative | Common Stock | 133,977 footnote F1 | - footnote F1 | - | |
| Michael F. Maclean - Officer | Derivative | Stock Option (Right to Buy) | 92,000 | - footnote F2 | - | |
| Michael F. Maclean - Officer | Derivative | Stock Option (Right to Buy) | 131,250 | - footnote F2 | - | |
| Michael F. Maclean - Officer | Derivative | Stock Option (Right to Buy) | 148,000 | - footnote F2 | - | |
| Michael F. Maclean - Officer | Derivative | Stock Option (Right to Buy) | 60,125 | - footnote F2 | - | |
| Michael F. Maclean - Officer | Derivative | Stock Option (Right to Buy) | 106,000 | - footnote F2 | - | |
| Michael F. Maclean - Officer | Derivative | Stock Option (Right to Buy) | 50,000 | - footnote F2 | - | |
| ||||||
| Simona Skerjanec | Derivative | Common Stock | 6,692 footnote F1 | - footnote F1 | - | |
| Simona Skerjanec | Derivative | Stock Option (Right to Buy) | 10,034 | - footnote F2 | - | |
| Simona Skerjanec | Derivative | Stock Option (Right to Buy) | 42,308 | - footnote F2 | - | |
| ||||||
| Steven George Hughes - Officer | Derivative | Common Stock | 115,857 footnote F1 | - footnote F1 | - | |
| Steven George Hughes - Officer | Derivative | Stock Option (Right to Buy) | 73,342 | - footnote F2 | - | |
| Steven George Hughes - Officer | Derivative | Stock Option (Right to Buy) | 74,000 | - footnote F2 | - | |
| Steven George Hughes - Officer | Derivative | Stock Option (Right to Buy) | 49,333 | - footnote F2 | - | |
| Steven George Hughes - Officer | Derivative | Stock Option (Right to Buy) | 68,458 | - footnote F2 | - | |
| Steven George Hughes - Officer | Derivative | Stock Option (Right to Buy) | 50,000 | - footnote F2 | - | |
| ||||||
| Sarah Boyce - Officer | Derivative | Common Stock | 474,861 footnote F1 | - footnote F1 | - | |
| Sarah Boyce - Officer | Derivative | Stock Option (Right to Buy) | 386,015 | - footnote F2 | - | |
| Sarah Boyce - Officer | Derivative | Stock Option (Right to Buy) | 300,000 | - footnote F2 | - | |
| Sarah Boyce - Officer | Derivative | Stock Option (Right to Buy) | 300,000 | - footnote F2 | - | |
| Sarah Boyce - Officer | Derivative | Stock Option (Right to Buy) | 425,000 | - footnote F2 | - | |
| Sarah Boyce - Officer | Derivative | Stock Option (Right to Buy) | 400,000 | - footnote F2 | - | |
| Sarah Boyce - Officer | Derivative | Stock Option (Right to Buy) | 200,000 | - footnote F2 | - | |
| Sarah Boyce - Officer | Derivative | Stock Option (Right to Buy) | 165,000 | - footnote F2 | - | |
| ||||||
| John B. Moriarty - Officer | Derivative | Common Stock | 92,054 footnote F1 | - footnote F1 | - | |
| John B. Moriarty - Officer | Derivative | Stock Option (Right to Buy) | 50,000 | - footnote F2 | - | |
| John B. Moriarty - Officer | Derivative | Stock Option (Right to Buy) | 160,000 | - footnote F2 | - | |
| ||||||
| W. Michael Flanagan - Officer | Derivative | Common Stock | 150,365 footnote F1 | - footnote F1 | - | |
| W. Michael Flanagan - Officer | Derivative | Stock Option (Right to Buy) | 25,000 | - footnote F2 | - | |
| W. Michael Flanagan - Officer | Derivative | Stock Option (Right to Buy) | 66,500 | - footnote F2 | - | |
| W. Michael Flanagan - Officer | Derivative | Stock Option (Right to Buy) | 96,000 | - footnote F2 | - | |
| W. Michael Flanagan - Officer | Derivative | Stock Option (Right to Buy) | 72,000 | - footnote F2 | - | |
| W. Michael Flanagan - Officer | Derivative | Stock Option (Right to Buy) | 88,000 | - footnote F2 | - | |
| W. Michael Flanagan - Officer | Derivative | Stock Option (Right to Buy) | 50,000 | - footnote F2 | - | |
| ||||||
| Troy Edward Wilson | Derivative | Common Stock | 65,091 footnote F1 | - footnote F1 | - | |
| Troy Edward Wilson | Derivative | Common Stock | 13,711 footnote F1 | - footnote F1 | - | |
| Troy Edward Wilson | Derivative | Stock Option (Right to Buy) | 10,034 | - footnote F2 | - | |
| Troy Edward Wilson | Derivative | Stock Option (Right to Buy) | 13,489 | - footnote F2 | - | |
| Troy Edward Wilson | Derivative | Stock Option (Right to Buy) | 15,000 | - footnote F2 | - | |
| ||||||
 Kathleen P. Gallagher - Officer | Derivative | Common Stock | 80,303 footnote F1 | - footnote F1 | - | |
| Kathleen P. Gallagher - Officer | Derivative | Stock Option (Right to Buy) | 22,321 | - footnote F2 | - | |
| Kathleen P. Gallagher - Officer | Derivative | Stock Option (Right to Buy) | 13,829 | - footnote F2 | - | |
| Kathleen P. Gallagher - Officer | Derivative | Stock Option (Right to Buy) | 9,244 | - footnote F2 | - | |
| Kathleen P. Gallagher - Officer | Derivative | Stock Option (Right to Buy) | 13,352 | - footnote F2 | - | |
| Kathleen P. Gallagher - Officer | Derivative | Stock Option (Right to Buy) | 27,584 | - footnote F2 | - | |
| Kathleen P. Gallagher - Officer | Derivative | Stock Option (Right to Buy) | 42,480 | - footnote F2 | - | |
| Kathleen P. Gallagher - Officer | Derivative | Stock Option (Right to Buy) | 13,520 | - footnote F2 | - | |
| Kathleen P. Gallagher - Officer | Derivative | Stock Option (Right to Buy) | 16,000 | - footnote F2 | - | |
| Kathleen P. Gallagher - Officer | Derivative | Stock Option (Right to Buy) | 50,000 | - footnote F2 | - | |
| ||||||
| Noreen Henig | Derivative | Common Stock | 6,692 footnote F1 | - footnote F1 | - | |
| Noreen Henig | Derivative | Stock Option (Right to Buy) | 10,034 | - footnote F2 | - | |
| Noreen Henig | Derivative | Stock Option (Right to Buy) | 13,489 | - footnote F2 | - | |
| Noreen Henig | Derivative | Stock Option (Right to Buy) | 22,000 | - footnote F2 | - | |
| Noreen Henig | Derivative | Stock Option (Right to Buy) | 22,000 | - footnote F2 | - | |
| Noreen Henig | Derivative | Stock Option (Right to Buy) | 15,000 | - footnote F2 | - | |
| Noreen Henig | Derivative | Stock Option (Right to Buy) | 11,323 | - footnote F2 | - | |
| Noreen Henig | Derivative | Stock Option (Right to Buy) | 9,534 | - footnote F2 | - | |
| ||||||
| Jean Jinsun Kim | Derivative | Common Stock | 6,692 footnote F1 | - footnote F1 | - | |
| Jean Jinsun Kim | Derivative | Stock Option (Right to Buy) | 10,034 | - footnote F2 | - | |
| Jean Jinsun Kim | Derivative | Stock Option (Right to Buy) | 13,489 | - footnote F2 | - | |
| Jean Jinsun Kim | Derivative | Stock Option (Right to Buy) | 22,000 | - footnote F2 | - | |
| Jean Jinsun Kim | Derivative | Stock Option (Right to Buy) | 22,000 | - footnote F2 | - | |
| Jean Jinsun Kim | Derivative | Stock Option (Right to Buy) | 30,000 | - footnote F2 | - | |
| ||||||
 Arthur A. Levin | Derivative | Common Stock | 16,562 footnote F1 | - footnote F1 | - | |
| Arthur A. Levin | Derivative | Common Stock | 131,372 footnote F1 | - footnote F1 | - | |
| Arthur A. Levin | Derivative | Stock Option (Right to Buy) | 10,034 | - footnote F2 | - | |
| Arthur A. Levin | Derivative | Stock Option (Right to Buy) | 13,489 | - footnote F2 | - | |
| Arthur A. Levin | Derivative | Stock Option (Right to Buy) | 144,000 | - footnote F2 | - | |
| Arthur A. Levin | Derivative | Stock Option (Right to Buy) | 115,500 | - footnote F2 | - | |
| Arthur A. Levin | Derivative | Stock Option (Right to Buy) | 12,500 | - footnote F2 | - | |
| ||||||
 Edward M. Md Kaye | Derivative | Common Stock | 6,692 footnote F1 | - footnote F1 | - | |
| Edward M. Md Kaye | Derivative | Stock Option (Right to Buy) | 10,034 | - footnote F2 | - | |
| Edward M. Md Kaye | Derivative | Stock Option (Right to Buy) | 13,489 | - footnote F2 | - | |
| Edward M. Md Kaye | Derivative | Stock Option (Right to Buy) | 22,000 | - footnote F2 | - | |
| Edward M. Md Kaye | Derivative | Stock Option (Right to Buy) | 22,000 | - footnote F2 | - | |
| Edward M. Md Kaye | Derivative | Stock Option (Right to Buy) | 15,000 | - footnote F2 | - | |
| Edward M. Md Kaye | Derivative | Stock Option (Right to Buy) | 11,323 | - footnote F2 | - | |
| Edward M. Md Kaye | Derivative | Stock Option (Right to Buy) | 9,534 | - footnote F2 | - | |
| ||||||
| Carsten Boess | Derivative | Common Stock | 6,692 footnote F1 | - footnote F1 | - | |
| Carsten Boess | Derivative | Stock Option (Right to Buy) | 10,034 | - footnote F2 | - | |
| Carsten Boess | Derivative | Stock Option (Right to Buy) | 13,489 | - footnote F2 | - | |
| Carsten Boess | Derivative | Stock Option (Right to Buy) | 22,000 | - footnote F2 | - | |
| Carsten Boess | Derivative | Stock Option (Right to Buy) | 22,000 | - footnote F2 | - | |
| Carsten Boess | Derivative | Stock Option (Right to Buy) | 15,000 | - footnote F2 | - | |
| Carsten Boess | Derivative | Stock Option (Right to Buy) | 20,858 | - footnote F2 | - | |
| ||||||
| Eric Mosbrooker - Officer | Derivative | Common Stock | 79,413 footnote F1 | - footnote F1 | - | |
| Eric Mosbrooker - Officer | Derivative | Stock Option (Right to Buy) | 177,188 | - footnote F2 | - | |
| Eric Mosbrooker - Officer | Derivative | Stock Option (Right to Buy) | 50,000 | - footnote F2 | - | |
| ||||||
 Charles Calderaro III - Officer | Derivative | Common Stock | 98,547 footnote F1 | - footnote F1 | - | |
| Charles Calderaro III - Officer | Derivative | Stock Option (Right to Buy) | 80,000 | - footnote F2 | - | |
| ||||||
| Steven George Hughes - Officer | Open-market sale | Common Stock | 2,017 footnote F1 | $72.45 | $146K | |
| Steven George Hughes - Officer | Open-market sale | Common Stock | 2,878 footnote F1 | $72.45 | $209K | |
| ||||||
| Sarah Boyce - Officer | Open-market sale | Common Stock | 6,394 footnote F1 | $72.45 | $463K | |
| Sarah Boyce - Officer | Open-market sale | Common Stock | 7,993 footnote F1 | $72.45 | $579K | |
| ||||||
| W. Michael Flanagan - Officer | Open-market sale | Common Stock | 3,976 footnote F1 | $72.45 | $288K | |
| W. Michael Flanagan - Officer | Open-market sale | Common Stock | 2,558 footnote F1 | $72.45 | $185K | |
| ||||||
| Michael F. Maclean - Officer | Open-market sale | Common Stock | 1,807 footnote F1 | $72.45 | $131K | |
| Michael F. Maclean - Officer | Open-market sale | Common Stock | 2,735 footnote F1 | $72.45 | $198K | |
| ||||||
| Arthur A. Levin - Director | Open-market sale | Common Stock | 1,758 footnote F1 | $72.45 | $127K | |
| ||||||
| Teresa McCarthy - Officer | Open-market sale | Common Stock | 1,476 footnote F1 | $72.45 | $107K | |
| Teresa McCarthy - Officer | Open-market sale | Common Stock | 1,453 footnote F1 | $72.45 | $105K | |
| ||||||
| Steven George Hughes - Officer | Option exercise | Common Stock | 2,209 | $10.16 | $22K | |
| Steven George Hughes - Officer | Open-market sale | Common Stock | 2,209 | $47.54 footnote F2 | $105K | |
| Steven George Hughes - Officer | Option exercise | Stock Option (Right to Buy) | 2,209 | $0.00 | - | |
| ||||||
| Teresa McCarthy - Officer | Option exercise | Common Stock | 20,000 | $22.34 | $447K | |
| Teresa McCarthy - Officer | Open-market sale | Common Stock | 20,000 | $50.15 footnote F2 | $1.00M | |
| Teresa McCarthy - Officer | Option exercise | Stock Option (Right to Buy) | 20,000 | $0.00 | - | |
| ||||||
| Eric Mosbrooker - Officer | Option exercise | Common Stock | 6,562 | $9.05 | $59K | |
| Eric Mosbrooker - Officer | Open-market sale | Common Stock | 6,562 | $45.38 footnote F2 | $298K | |
| Eric Mosbrooker - Officer | Option exercise | Stock Option (Right to Buy) | 6,562 | $0.00 | - | |
| ||||||
| Steven George Hughes - Officer | Option exercise | Common Stock | 2,208 | $10.16 | $22K | |
| Steven George Hughes - Officer | Open-market sale | Common Stock | 2,208 | $40.58 | $90K | |
| Steven George Hughes - Officer | Option exercise | Stock Option (Right to Buy) | 2,208 | $0.00 | - | |
| Teresa McCarthy - Officer | Option exercise | Common Stock | 15,000 | $22.34 | $335K | |
| Teresa McCarthy - Officer | Open-market sale | Common Stock | 15,000 | $41.41 | $621K | |
| Teresa McCarthy - Officer | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Steven George Hughes - Officer | Option exercise | Common Stock | 1,542 | $6.57 | $10K | |
| Steven George Hughes - Officer | Open-market sale | Common Stock | 1,542 | $45.41 | $70K | |
| Steven George Hughes - Officer | Option exercise | Stock Option (Right to Buy) | 1,542 | $0.00 | - | |
| W. Michael Flanagan - Officer | Option exercise | Common Stock | 20,000 | $14.22 | $284K | |
| W. Michael Flanagan - Officer | Open-market sale | Common Stock | 20,000 | $38.94 | $779K | |
| W. Michael Flanagan - Officer | Option exercise | Stock Option (Right to Buy) | 20,000 | $0.00 | - | |
Item 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
Item 5.07
Item 8.01, 9.01
RNAM insider trading FAQ
What is the latest insider trade for RNAM?
Avidity Biosciences, Inc. (RNAM) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-02-27. The full record for RNAM runs to 59 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying RNAM stock?
No insider purchases of RNAM were filed in the last 90 days.
How many insiders are selling RNAM stock?
No insider sales of RNAM were filed in the last 90 days. 58 sales are on record for this company.
Where can I see RNAM SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects RNAM Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Teresa McCarthy view on EDGAR
- - Tamar Thompson view on EDGAR
- - Michael F. Maclean view on EDGAR
- - Simona Skerjanec view on EDGAR
- - Steven George Hughes view on EDGAR
- - Sarah Boyce view on EDGAR
- - John B. Moriarty view on EDGAR
- - W. Michael Flanagan view on EDGAR
- - Troy Edward Wilson view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where RNAM's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow RNAM with a 7-day demo
- RNAM on your watchlist
- Every RNAM Form 4 filing on record
- Up to 3 months of RNAM price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
